-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 12, Haichuang Pharmaceutical announced that its "HC-1119 New Coronary Inpatient Treatment Phase 2/3 Clinical Trial" application has been approved by the Brazilian Health Supervision Agency (ANVISA), and relevant clinical trials will be officially launched in Brazil
.
It is reported that the trial is a placebo-controlled, based on standard treatment, to evaluate the efficacy and safety of HC-1119 in the treatment of hospitalized patients with new coronary disease
HC-1119 is an androgen receptor (AR) inhibitor.
It is one of the core products under development of Haichuang Pharmaceutical.
It is simultaneously carrying out a global multi-center clinical phase 3 trial for the treatment of prostate cancer and a clinical phase 3 trial in China
.
If this article violates your rights, please contact us